Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that management will present a company overview at the following investor conferences:
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that management will present a company overview at the following investor conferences:
- Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019, at 10:00 a.m. Eastern Time in Boston, MA
- Oppenheimer's 29th Annual Healthcare Conference on Tuesday, March 19, 2019, at 9:10 a.m. Eastern Time in New York, NY
About Aura Biosciences
Aura Biosciences is developing a new class of therapies to selectively target and destroy cancer cells. Its lead program, AU-011 in primary choroidal melanoma, is being developed under a CRADA with the National Cancer Institute (NCI), part of the National Institutes of Health. For more information, visit www.aurabiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005999/en/
Contacts
Media:
David Rosen
Argot Partners
212.600.1902 | david.rosen@argotpartners.com
Investors:
Joseph Rayne
Argot Partners
617.340.6075 | joseph@argotpartners.com
Source: Aura Biosciences
View this news release online at:
http://www.businesswire.com/news/home/20190305005999/en
